Question 1
Question
Clinical practice guidelines, meta-analysis, and systematic reviews are the highest ranked forms of evidence.
Question 2
Question
Māori are 3.4 times, and Pacific peoples 3.9 times, more likely to be admitted to hospital with asthma than Europeans or other New Zealanders.
Question 3
Question
When diagnosing asthma there is no single “gold standard” test, and we must assess the pattern of [blank_start]signs and symptoms[blank_end](wheezing, breathlessness, chest tightness, and coughing, particularly at [blank_start]night[blank_end] or [blank_start]early[blank_end] in the morning). We can also measure [blank_start]expiratory airflow[blank_end] on more than one occasion, and assess [blank_start]response[blank_end] to inhaled bronchodilator +/- inhaled corticosteroid.
Answer
-
signs and symptoms
-
night
-
early
-
expiratory airflow
-
response
Question 4
Question
Ideal PEFR values depend on height and sex.
Question 5
Question
Which of these is NOT a principle of asthma treatment?
Question 6
Question
Goals of asthma treatment are about maintaining long-term control using the [blank_start]least[blank_end] amount of medications and [blank_start]minimising[blank_end] adverse effects.
We want to prevent chronic [blank_start]symptoms[blank_end], require infrequent use ([blank_start]2[blank_end] or fewer days/week) of SABA, maintain normal or near-normal [blank_start]pulmonary[blank_end] function and maintain [blank_start]activity[blank_end] levels. We should assure patients’ and families’ [blank_start]satisfaction[blank_end] with asthma care. We also want to prevent exacerbations, the need for [blank_start]hospitalisation[blank_end], and prevent progressive [blank_start]loss[blank_end] of lung function.
Answer
-
least
-
minimising
-
symptoms
-
2
-
pulmonary
-
activity
-
satisfaction
-
hospitalisation
-
loss
Question 7
Question
Which of these is not a drug delivery device?
Question 8
Question
Treatment steps:
1. At initial diagnosis, all patients should use a [blank_start]SABA[blank_end], as required..
2. Add an [blank_start]ICS[blank_end] if patients have symptoms for more than [blank_start]two[blank_end] weeks. Often a big decision! (The usual dose in adults is [blank_start]budesonide 400 mcg[blank_end]/day.)
3. If control is not adequate, [blank_start]ICS dose[blank_end] can be increased.
4. If control is not adequate, combine [blank_start]ICS with a LABA[blank_end]. ([blank_start]Formoterol+budesonide[blank_end] can be used as a preventer and replace SABA.)
Patients can step up or down in order to achieve and maintain control.
Check adherence and inhaler [blank_start]technique[blank_end] at each step of the way!
Answer
-
SABA
-
ICS
-
two
-
budesonide 400 mcg
-
ICS dose
-
ICS with a LABA
-
Formoterol+budesonide
-
technique